Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 323
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Pharmaceutical / Industry
BO21015
2008-000662-23, NCT00700180
Last Modified:
6/15/2007
 
First Published:
5/23/2005
2.
Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 to 75
Other
FRE-FNCLCC-ACCORD-11/0402
EU-20512, NCT00112658
3.
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
SGI-RUB-048
NCT00113256
Last Modified:
2/15/2007
 
First Published:
3/13/2006
4.
Phase II/III Randomized Study of Fluorouracil, Cisplatin, and Radiotherapy Versus Gemcitabine Hydrochloride and Oxaliplatin in Patients With Unresectable, Nonmetastatic Cancer of the Biliary Tract
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Other, Pharmaceutical / Industry
FFCD-9902
SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
Last Modified:
4/30/2008
 
First Published:
1/1/2002
5.
Phase III Randomized Study of Immediate Versus Deferred Adjuvant Chemotherapy After Radical Cystectomy in Patients With Stage III or IV Transitional Cell Carcinoma of the Bladder Urothelium
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Not specified
NCI, Other
EORTC-30994
ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, JUG-EORTC-30994, NORDIC-EORTC-30994, SEUG-EORTC-30994, SWOG-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756, EORTC-30994
Last Modified:
9/26/2008
 
First Published:
2/20/2004
6.
Phase III Randomized Study of Salvage Chemotherapy Comprising Dexamethasone, Cisplatin, and Gemcitabine Versus a Standard Platinum-Based Regimen (Dexamethasone, Cisplatin, and High-Dose Cytarabine) Before Autologous Stem Cell Transplantation and With or Without Maintenance Rituximab in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
16 to 65
Other
CAN-NCIC-LY12
NCT00078949, LY12
7.
Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
16 to 65
Pharmaceutical / Industry
7581
NCT00089817
Last Modified:
5/8/2007
 
First Published:
5/23/2005
8.
Phase III Randomized Study of Gemcitabine in Combination With Cisplatin Versus Carboplatin in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
CRUK-BTOG2-LU3005
EU-20510, NCT00112710
9.
Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
20 to 75
Other
WJTOG0101
NCT00139971
10.
Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
GEFCAPI O2
NCT00126269
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute